key: cord-0255571-66afjpda
authors: Rathee, Sanjay; MacMahon, Meabh; Liu, Anika; Katritsis, Nicholas; Youssef, Gehad; Hwang, Woochang; Wollman, Lilly; Han, Namshik
title: DILIC: An AI based classifier to search for Drug-Induced Liver Injury literature
date: 2022-02-14
journal: bioRxiv
DOI: 10.1101/2022.02.12.480184
sha: d478112046d9d7ae4d74039cae4a2f22d19f390a
doc_id: 255571
cord_uid: 66afjpda

Drug-Induced Liver Injury (DILI) is a class of Adverse Drug Reactions (ADR) which causes problems in both clinical and research settings. It is the most frequent cause of acute liver failure in the majority of western countries and is a major cause of attrition of novel drug candidates. Manual trawling of literature for is the main route of deriving information on DILI from research studies. This makes it an inefficient process prone to human error. Therefore, an automatized AI model capable of retrieving DILI-related papers from the huge ocean of literature could be invaluable for the drug discovery community. In this project, we built an artificial intelligence (AI) model combining the power of Natural Language Processing (NLP) and Machine Learning (ML) to address this problem. This model uses NLP to filter out meaningless text (e.g. stopwords) and uses customized functions to extract relevant keywords as singleton, pair, triplet and so on. These keywords are processed by apriori pattern mining algorithm to extract relevant patterns which are used to estimate initial weightings for a ML classifier. Along with pattern importance and frequency, an FDA-approved drug list mentioning DILI adds extra confidence in classification. The combined power of these methods build a DILI classifier (DILIC) with 94.91% cross-validation and 94.14% external validation accuracy. To make DILIC as accessible as possible, including to researchers without coding experience, an R Shiny App capable of classifing single or multiple entries for DILI is developed to enhance ease of user experience and made available at https://researchmind.co.uk/diliclassifier/).

Drug-Induced Liver Injury (DILI) is a class of adverse drug reactions (ADR) which is an issue in both 22 clinical and research settings. Although DILI can be mild, resolving once administration of the problem 23 drug is discontinued, it lies on a spectrum and can also be severe. DILI is the most frequent cause of acute DILI from research studies. This is an inefficient process prone to human error and modern computational 30 techniques for mining textual data can improve it, a model capable of retrieving DILI-related papers from 31 the huge ocean of literature could be invaluable for the drug discovery community.

Natural language processing (NLP) involves using computational techniques to extract information and 33 insights from text data. Previous studies have applied NLP techniques to identify relevant literature for 34 challenges in drug discovery, including with the goal of drug repurposing Zhu et al. (2020) and collating 35 information on COVID-19 for researchers Wang and Lo (2021) . Additionally previous attempts have been 36 made to classify adverse drug events using NLP on available data Harpaz et al. (2014) . Databases of drug 37 side effects also contain DILI-related informationFDA (2021); Kuhn et al. (2016) . In this study NLP is 38 used to extract relevant patterns from literature and this knowledge is combined with information related to 39 DILI from publicly available databases. This combined information is used to train a classifier to classify 40 literature as DILI-related or not. Figure 1 highlights the flow of text processing for our model. Collect(tokens)

Along with the total frequency of a keyword set, the frequency of the keyword and its subsets in terms 69 of the number of papers (DILI positive or DILI negative) in which it appears was calculated. The pattern 70 mining ML algorithm Apriori was used for this. In this way, we included the frequency of a keyword set 71 and its subset as a factor for weighting that keyword set. A distributed processing-based implementation of 72 Apriori was used to minimize the overall processing time. 3), a list of drugs with DILI as adverse events or warning were extracted, and these drugs were given a 78 higher weight than others without such warnings. The side effects field of SIDER database for drugs was 79 helpful to add extra information into this highly weighted list. weight of a keyword was calculated by its total frequency, length, FDA and SIDER list presence or absence.

In equation (1), W T represents the total weight for a paper, key represents the weight for presence (1) Figure 2 shows the probability of every sample being positive. Any sample 93 with a probability higher than 50% is labelled as DILI positive. The cutoff of 50% can be adjusted to closer 94 reflect a real-world dataset which will have far more negative literature. 

The most effective model was Gradient Boosting Machines ( Figure 3 ) with 94.76% accuracy when applied 97 to the internal hold out test set of 2,842 papers, half of which were DILI positive and half DILI negative.

The inclusion of FDA and SIDER datasets improved the accuracy of the GBM model in the validation set 99 and on an additional external set ( Table 2 ). The final model is used to predict the labels for the external power to DILI C and there is still plenty of scope to adjust the weights for these steps. In addition, as other 118 databases related to drug toxicity and side effects are developed, these could be integrated to improve the 119 model. To make DILI C as accessible as possible, including to researchers without coding experience, an R 120 Shiny App capable of classifing single or multiple abstracts for DILI is developed to enhance ease of user 121 experience and made available at https://researchmind.co.uk/diliclassifier/).

DILI C is a novel tool to classify literature as related to DILI or not. This is significant as it has the potential 123 to aid researchers in drug-development and research settings during risk-assessment.

DILI C is implemented in such a way that it can be modified to classify any other drug adverse reaction 125 like DILI. Therefore, DILI C code available at GitHub could be useful for researchers working in the same 126 domain. A shiny app for DILI C makes it user-friendly.

SR is funded by JW Pharmaceutical. MM is an employee of Lifearc. NH and WH are funded by LifeArc.

advisor at Biorelate, Promatix, Standigm and VeraVerse.

CAMDA 2021

enIn silico modeling to optimize interpretation of liver 140 safety biomarkers in clinical trials

enText Mining 144 for Adverse Drug Events: the Promise, Challenges, and State of the Art

Drug-Induced Liver Injury -Types and Phenotypes

The SIDER database of drugs and side effects

Text mining approaches for dealing with the rapidly expanding literature 152 on COVID-19

enDrug Safety Sciences and the Bottleneck in Drug Development

Drug repurposing against Parkinson's disease by 157 text mining the scientific literature